FORMATO EUROPEO PER IL CURRICULUM VITAE

of 13 FORMATO EUROPEO PER IL CURRICULUM VITAE INFORMAZIONI PERSONALI Nome VITA GIUSEPPE Telefono +39 (090) 221 2793 Fax 0902212789 E-mail VITAG@UNIME.IT Nazionalità ITALIANA Data di Nascita 02/01/1952

of 13 ESPERIENZA LAVORATIVA Date (da - a) 01/11/1994 - Nome e indirizzo del datore di lavoro UNIVERSITÀ DI MESSINA, AOU POLICLINICO DI MESSINA Tipo di azienda o settore SANITÀ Tipo di impiego PROFESSORE ORDINARIO DI NEUROLOGIA Principali mansioni e responsabilità DAL 1/11/2009 DIRETTORE DELL'UNITÀ OPERATIVA COMPLESSA DI NEUROLOGIA E MALATTIE NEUROMUSCOLARI E DIRETTORE DEL DAI DI NEUROSCIENZE. DAL 2000 AL 2009 DIRETTORE DELL UOS DI NEUROBIOLOGIA CLINICA E MALATTIE NEUROMUSCOLARI. ISTRUZIONE E FORMAZIONE Date (da - a) 01/10/1985-30/09/1986 Nome e tipo di istituto di istruzione o formazione NEUROMUSCULAR CENTER, UNIVERSITY OF SOUTHERN CALIFORNIA, LOS ANGELES - STATI UNITI D'AMERICA di Studio CORSO DI PERFEZIONAMENTO Qualifica conseguita POST-DOCTORAL CERTIFICATION IN NEUROMUSCULAR DISEASES

of 13 Livello nella classificazione nazionale Date (da - a) 01/11/1976-31/10/1980 Nome e tipo di istituto di istruzione o formazione UNIVERSITÀ DI MESSINA, MESSINA - ITALIA di Studio SPEC.NE IN NEUROLOGIA Qualifica conseguita Livello nella classificazione nazionale 50/50 CON LODE Date (da - a) 01/10/1978-30/07/1979 Nome e tipo di istituto di istruzione o formazione MUSCULAR DYSTROPHY GROUP LABORATORY, UNIVERSITY OF NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE - GRAN BRETAGNA di Studio CORSO DI PERFEZIONAMENTO Qualifica conseguita RESEARCH FELLOWSHIP IN NEUROMUSCULAR DISEASES Livello nella classificazione nazionale Date (da - a) 01/11/1970-28/10/1976

of 13 Nome e tipo di istituto di istruzione o formazione UNIVERSITÀ DI MESSINA, MESSINA - ITALIA di Studio LAUREA IN MEDICINA E CHIRURGIA Qualifica conseguita Livello nella classificazione nazionale 110/110 CON LODE PUBBLICAZIONI FLAVOCOXID COUNTERACTS MUSCLE NECROSIS AND IMPROVES FUNCTIONAL PROPERTIES IN MDX MICE: A COMPARISON STUDY WITH METHYLPREDNISOLONE MESSINA S, BITTO A, AGUENNOUZ M, MAZZEO A, MIGLIORATO A, POLITO F, IRRERA N, ALTAVILLA D, VITA GL, RUSSO M, NARO A, DE PASQUALE MG, RIZZUTO E, MUSARÒ A, SQUADRITO F, VITA G MUSCLE DEGENERATION IN DYSTROPHIC MUSCLE IS EXACERBATED BY THE ENDOGENOUS INFLAMMATORY RESPONSE AND INCREASED OXIDATIVE STRESS. A KEY ROLE IN IS PLAYED BY NUCLEAR FACTOR (NF)-ΚB. WE SHOWED THAT NF-ΚB INHIBITION THROUGH COMPOUNDS WITH ALSO ANTIOXIDANT PROPERTIES HAS BENEFICIAL EFFECTS IN MDX MICE, THE MURINE MODEL OF DUCHENNE MUSCULAR DYSTROPHY (DMD), BUT THESE DRUGS ARE NOT AVAILABLE FOR CLINICAL STUDIES. WE EVALUATED WHETHER FLAVOCOXID, A MIXED FLAVONOID EXTRACT WITH ANTI-INFLAMMATORY, ANTIOXIDANT AND NF-ΚB INHIBITING PROPERTIES, HAS BENEFICIAL EFFECTS IN MDX MICE IN COMPARISON WITH METHYLPREDNISOLONE, THE GOLD STANDARD TREATMENT FOR DMD PATIENTS. FIVE-WEEK-OLD MDX MICE WERE TREATED FOR 5 WEEKS WITH FLAVOCOXID, METHYLPREDNISOLONE OR VEHICLE. THE EVALUATION OF IN VIVO AND EX VIVO FUNCTIONAL PROPERTIES AND MORPHOLOGICAL PARAMETERS WAS PERFORMED. SERUM SAMPLES WERE ASSAYED FOR OXIDATIVE STRESS MARKERS, CREATINE-KINASE (CK) AND LEUKOTRIENE B-4. CYCLOOXYGENASE-2 (COX-2), 5-LIPOXYGENASE (5 -LOX), TUMOR NECROSIS FACTOR-ALPHA, P-38, JNK1 EXPRESSION WAS EVALUATED IN MUSCLE BY WESTERN BLOT ANALYSIS. NF-ΚB BINDING ACTIVITY WAS INVESTIGATED BY ELECTROPHORESIS

of 13 MOBILITY SHIFT ASSAY. THE ADMINISTRATION OF FLAVOCOXID: (1) AMELIORATED FUNCTIONAL PROPERTIES IN VIVO AND EX VIVO; (2) REDUCED CK; (3) REDUCED THE EXPRESSION OF OXIDATIVE STRESS MARKERS AND OF INFLAMMATORY MEDIATORS; (4) INHIBITED NF-ΚB AND MITOGEN-ACTIVATED PROTEIN KINASES (MAPKS) SIGNAL PATHWAYS; (5) REDUCED MUSCLE NECROSIS AND ENHANCED REGENERATION. OUR RESULTS HIGHLIGHT THE DETRIMENTAL EFFECTS OF OXIDATIVE STRESS AND NF-ΚB, MAPKS AND COX/5-LOX PATHWAYS IN THE DYSTROPHIC PROCESS AND SHOW THAT FLAVOCOXID IS MORE EFFECTIVE IN MDX MICE THAN METHYLPREDNISOLONE. EXPERIMENTAL NEUROLOGY 2009 SEP 25. [EPUB AHEAD OF PRINT] ANNO: 2009 - ISBN: PSYCHOSOCIAL IMPACT OF PRESYMPTOMATIC GENETIC TESTING FOR TRANSTHYRETIN AMYLOIDOTIC POLYNEUROPATHY GRACEFFA A, RUSSO M, VITA GL, TOSCANO A, DATTOLA R, MESSINA C, VITA G, MAZZEO A. PRESYMPTOMATIC GENETIC TESTING OF AN UNTREATABLE DISEASE RAISES CLINICAL, ETHICAL, LEGAL AND PSYCHOSOCIAL QUESTIONS. INVESTIGATIONS IN SPECIFIC DISORDERS ARE NEEDED TO HELP IN UNDERSTANDING THE MOTIVATION FOR AND THE IMPACT OF GENETIC TESTING IN THE LIVES OF PERSONS AT RISK FOR THESE DISEASES. HERE, WE PERFORMED A LONGITUDINAL STUDY TO INVESTIGATE THE PSYCHOLOGICAL CONSEQUENCES OF PRESYMPTOMATIC GENETIC TESTING ON PEOPLE AT RISK FOR TRANSTHYRETIN-RELATED FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (TTR-FAP). THE AIM OF THE PRESENT STUDY WAS TO PROVIDE POSSIBLE GUIDELINES FOR GENETIC COUNSELLING AND PSYCHOSOCIAL SUPPORT. IMPACT OF EVENT SCALE REVISED (IES-R), HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS) AND SF-36 QUESTIONNAIRES WERE ADMINISTERED TO 18 ASYMPTOMATIC SUBJECTS BEFORE, IMMEDIATELY AFTER COMMUNICATION OF THE GENETIC TEST RESULT AND AFTER 3, 6 AND 26 MONTHS. OUR FINDINGS SHOWED EVIDENCE OF ANXIETY, DEPRESSION, AVOIDANCE OF THE DISEASE, AND PSYCHOLOGICAL DISTRESS, ESPECIALLY FOR WOMEN, INCLUDING THOSE WITH A NEGATIVE GENETIC TEST RESULT ( SURVIVOR GUILT ). A PSYCHOLOGICAL SUPPORT HAS TO BE PROVIDED BEFORE AND CONTINUED AT LONG TERM AFTER PRESYMPTOMATIC GENETIC TESTING FOR TTR-FAP IN PEOPLE WITH POSITIVE RESULT AS WELL AS IN THOSE WITH NEGATIVE RESULT. NEUROMUSCULAR DISORDERS 2009;19:44-48. ANNO: 2009 - ISBN:

of 13 IMMUNE-MEDIATED RIPPLING MUSCLE DISEASE WITH MYASTHENIA GRAVIS: A REPORT OF SEVEN PATIENTS WITH LONG-TERM FOLLOW- UP IN TWO SCHOSER B, JACOB S, HILTON-JONES D, MÜLLER-FELBER W, KUBISCH C, CLAUS D, GOEBEL HH, VITA G, VINCENT A, TOSCANO A, BERGH PV. WE REPORT SEVEN PATIENTS WITH IMMUNE-MEDIATED RIPPLING MUSCLE DISEASE (IRMD) AND CHR-ANTIBODY POSITIVE MYASTHENIA GRAVIS (MG) WITHOUT GERMLINE CAVEOLIN-3 GENE MUTATIONS. WE DESCRIBE THE FOLLOW-UP OF TWO PATIENTS AND THE CLINICAL FEATURES OF FIVE NEW PATIENTS (1 FEMALE, 4 MALE, AGED 32 TO 69 YEARS). THESE PRESENTED WITH SIGNIFICANT GENERALIZED, EXERCISE-INDUCED AND ELECTRICALLY-SILENT MUSCLE RIPPLING WITH MYALGIA, COMBINED WITH GENERALIZED MG. IN TWO OF THE SEVEN PATIENTS, MG APPEARED BEFORE IRMD. MEDIASTINAL IMAGING EXCLUDED THYMIC ALTERATIONS IN ALL, ALTHOUGH TWO HAD OTHER COINCIDENT TUMOURS. MYALGIA AND RIPPLING WERE AGGRAVATED BY ACETYLCHOLINESTERASE-INHIBITOR TREATMENT. GENERALIZED MG AND IRMD WERE SUCCESSFULLY TREATED WITH PLASMA EXCHANGE, STEROIDS AND AZATHIOPRINE IN THE TWO PATIENTS FOLLOWED LONG-TERM. MUSCLE MORPHOLOGY OF FIVE PATIENTS SHOWED A MINIMAL MYOPATHIC PATTERN WITH RARE LYMPHOHISTIOCYTIC INFILTRATION. IN FOUR PATIENTS, SARCOLEMMAL CAVEOLIN-3, AND DYSFERLIN IMMUNOFLUORESCENCE STAINING WAS MODERATELY REDUCED IN A MOSAIC PATTERN, BUT CAVEOLIN-3 PROTEIN ON WESTERN BLOTS WAS CLEARLY REDUCED ONLY IN TWO. NOTABLY, ELECTRON MICROSCOPY SHOWED THAT CAVEOLAE WERE ALMOST COMPLETELY LOST AT THE SARCOLEMMA IN THE THREE BIOPSIES EXAMINED BUT NOT IN ENDOTHELIUM. ANTIBODIES TARGETING HIGH MOLECULAR WEIGHT MUSCLE PROTEINS, LIKELY ASSOCIATED WITH THE NEUROMUSCULAR ENDPLATE AND SARCOLEMMA, WERE FOUND IN THE IRMD PATIENTS BUT ALSO IN AGE-MATCHED MG PATIENTS WITHOUT IRMD. SINCE THE GENERALIZED MG AND IRMD IMPROVED WITH IMMUNOSUPPRESSIVE TREATMENTS, IT IS LIKELY THAT BOTH ARE CAUSED BY AUTOANTIBODIES, BUT THE TARGET FOR PATHOGENIC ANTIBODIES IN IRMD REQUIRES FURTHER STUDY. NEUROMUSCULAR DISORDERS 2009;19:223-228. ANNO: 2009 - ISBN: NATURAL HISTORY OF CMT1A INCLUDING QOL: A 2 YEAR PROSPECTIVE STUDY

of 13 PADUA L, PAREYSON D, APRILE I, CAVALLARO T, QUATTRONE A, RIZZUTO N, VITA G, TONALI P, SCHENONE A. THE ITALIAN CMT STUDY GROUP PERFORMED A MULTICENTRE, MULTIDIMENSIONAL, LONGITUDINAL 2-YEAR FOLLOW-UP STUDY USING VALIDATED MEASUREMENTS OF NEUROLOGICAL IMPAIRMENT, DISABILITY AND QUALITY OF LIFE. THE AIM OF THE STUDY WAS TO EVALUATE THE NATURAL HISTORY OF CLINICAL FEATURES, DISABILITY AND QOL IN PATIENTS WITH CMT1A. ON CLINICAL EXAMINATION, CMT1A PATIENTS SHOWED A SIGNIFICANT REDUCTION IN MUSCLE STRENGTH AND SENSORY FUNCTION DURING THE 2-YEAR FOLLOW-UP PERIOD. HOWEVER, THERE WAS NO WORSENING OF QOL OR DISABILITY, NOR WAS DEPRESSION OBSERVED. THE DISCREPANCY BETWEEN THE EVOLUTION OF CLINICAL FEATURES AND THE EVOLUTION OF QOL AND DISABILITY MAY BE DUE TO THE DEVELOPMENT OF COMPENSATORY STRATEGIES THAT HELP PATIENTS COPE WITH THE SLOW PROGRESSION OF THE DISEASE. OUR OBSERVATIONS PROVIDE INFORMATION WHICH MAY BE USEFUL WHEN DESIGNING CLINICAL TRIALS IN CMT. NEUROMUSCULAR DISORDERS 2008;18:199-203. ANNO: 2008 - ISBN: NUCLEAR FACTOR-KAPPAB ACTIVATION AND DIFFERENTIAL EXPRESSION OF SURVIVIN AND BCL-2 IN HUMAN GRADE 2-4 ASTROCYTOMAS ANGILERI FF, AGUENNOUZ M, CONTI A, LA TORRE D, CARDALI S, CRUPI R, TOMASELLO C, GERMANÒ A, VITA G, TOMASELLO F. BACKGROUND. ANTIAPOPTOTIS RESULTING FROM HYPERACTIVATION OF THE TRANSCRIPTION FACTOR NF-KB HAS BEEN DESCRIBED IN SEVERAL CANCER TYPES. IT IS TRIGGERED BY THE INTERACTION OF THE TUMOR NECROSIS FACTOR (TNF) WITH ITS RECEPTORS AND RECRUITMENT OF THE INTERMEDIATE FACTOR TNF-RECEPTOR ASSOCIATED FACTOR (TRAF) 2. THE NF-KB TRANSCRIPTIONAL ACTIVITY COULD AMPLIFY THE EXPRESSION OF ANTIAPOPTOTIC GENES. THE AUTHORS INVESTIGATED THE ACTIVITY OF NF-KB, AND THE MRNA EXPRESSION OF TNFALPHA, TNFALPHA RECEPTOR, TRAF1, TRAF2, AND TRAF-ASSOCIATED NF-KB ACTIVATOR (TANK), AND THE ANTIAPOPTOTIC GENES BCL-2, C-IAP 1 AND 2, AND SURVIVIN IN HUMAN ASTROCYTIC TUMORS. METHODS. EIGHT LOW-GRADE ASTROCYTOMAS (LGA), 10 ANAPLASTIC ASTROCYTOMAS (AAS), 10 GLIOBLASTOMA MULTIFORME (GBM) SAMPLES WERE USED; 4 SAMPLES OF NORMAL BRAIN TISSUE WERE USED AS CONTROLS. THE NF-KB ACTIVATION WAS ANALYZED BY ELECTROPHORETIC MOBILITY SHIFT ASSAY; TRAF1, TRAF2, TANK/I-TRAF, BCL-2, C-IAP 1 AND 2, AND SURVIVIN MRNA EXPRESSIONS WERE STUDIED USING REAL-TIME

of 13 QUANTITATIVE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION. RESULTS. NF-KB HYPERACTIVITY WAS DETECTED IN TUMOR SAMPLES. MRNA OF ANTIAPOPTOTIC GENES, PARTICULARLY BCL-2 AND SURVIVIN, WAS HYPEREXPRESSED IN GLIOMAS. INTERESTINGLY, BCL-2 WAS HYPEREXPRESSED IN LGAS, WHEREAS A VERY HIGH LEVEL OF SURVIVIN FEATURED HIGH-GRADE GLIOMAS. THE DIFFERENTIAL EXPRESSION OF ANTIAPOPTOTIC GENES YIELDED A TIGHT CLUSTERING OF ALL LGA AND NEARLY ALL GBM SAMPLES IN CLUSTER ANALYSIS. CONCLUSIONS. NF-KB AND FACTORS INVOLVED IN ITS INTRACELLULAR ACTIVATION WERE UP-REGULATED IN GLIOMAS. NF-KB-ACTIVATED ANTIAPOPTOTIC GENES WERE HYPEREXPRESSED IN TUMOR SAMPLES, BUT SHOWED A DIFFERENTIAL EXPRESSION WITH HIGHER LEVELS OF BCL-2 IN LGAS AND HIGHER LEVELS OF SURVIVIN IN GBMS. CANCER 2008;112:2258-2266. ANNO: 2008 - ISBN: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PHENYLBUTYRATE IN SPINAL MUSCULAR ATROPHY. MERCURI E, BERTINI E, MESSINA S, SOLARI A, D AMICO A, ANGELOZZI C, BATTINI R, BERARDINELLI A, BOFFI P, BRUNO C, CINI C, COLITTO F, KINALI M, MINETTI C, MONGINI T, MORANDI L, NERI G, ORCESI S, PANE M, PELLICCIONI M, PINI A, TIZIANO FD, VITA G, BRAHE C OBJECTIVE: TO ASSESS THE EFFICACY OF PHENYLBUTYRATE (PB) IN PATIENTS WITH SPINAL MUSCULAR ATROPHY IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL INVOLVING 10 ITALIAN CENTERS. METHODS: ONE HUNDRED SEVEN CHILDREN WERE ASSIGNED TO RECEIVE PB (500 MG/KG/DAY) OR MATCHING PLACEBO ON AN INTERMITTENT REGIMEN (7 DAYS ON/7 DAYS OFF) FOR 13 WEEKS. THE HAMMERSMITH FUNCTIONAL MOTOR SCALE (PRIMARY OUTCOME MEASURE), MYOMETRY, AND FORCED VITAL CAPACITY WERE ASSESSED AT BASELINE AND AT WEEKS 5 AND 13. RESULTS: BETWEEN JANUARY AND SEPTEMBER 2004, 107 PATIENTS AGED 30 TO 154 MONTHS WERE ENROLLED. PB WAS WELL TOLERATED, WITH ONLY ONE CHILD WITHDRAWING BECAUSE OF ADVERSE EVENTS. MEAN IMPROVEMENT IN FUNCTIONAL SCORE WAS 0.60 IN THE PB ARM AND 0.73 IN PLACEBO ARM (P _ 0.70). CHANGES IN THE SECONDARY ENDPOINTS WERE ALSO SIMILAR IN THE TWO STUDY ARMS. CONCLUSIONS: PHENYLBUTYRATE WAS NOT EFFECTIVE AT THE REGIMEN, SCHEDULE, AND DURATION USED IN THIS STUDY. NEUROLOGY 2007;68:51-55. ANNO: 2007 - ISBN:

of 13 VEGF OVEREXPRESSION VIA ADENO-ASSOCIATED VIRUS GENE TRANSFER PROMOTES SKELETAL MUSCLE REGENERATION AND ENHANCES MUSCLE FUNCTION IN MDX MICE. MESSINA S, MAZZEO A, BITTO A, AGUENNOUZ M, MIGLIORATO A, DE PASQUALE MG, MINUTOLI L, ALTAVILLA D, ZENTILIN L, GIACCA M, SQUADRITO F, VITA G. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IS A MAJOR REGULATOR OF PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS. RECENTLY IT WAS REPORTED THAT THE DELIVERY OF VEGF USING RECOMBINANT ADENOASSOCIATED VIRUS (RAAV) VECTORS REDUCES MUSCLE DAMAGE AND PROMOTES MUSCLE REGENERATION IN DIFFERENT EXPERIMENTAL MODELS OF MUSCLE NECROSIS. WE DEMONSTRATE THAT INTRAMUSCULAR ADMINISTRATION OF RAAVVEGF IMPROVED PATHOPHYSIOLOGY OF THE MDX MOUSE, A MODEL OF DUCHENNE MUSCULAR DYSTROPHY (DMD). ONE MONTH AFTER INJECTION, RAAV-VEGF-TREATED MUSCLES SHOWED AUGMENTED EXPRESSION OF VEGF AND IMMUNOLOCALIZATION OF ITS RECEPTOR, VEGFR-2. VEGF-TREATED MDX MICE SHOWED INCREASED FORELIMB STRENGTH AND STRENGTH NORMALIZED TO WEIGHT. TREATMENT REDUCED NECROTIC FIBERS AREA AND INCREASED REGENERATING FIBERS AREA WITH AN AUGMENTED NUMBER OF MYOGENIN-POSITIVE SATELLITE CELLS AND MYONUCLEI, AND OF DEVELOPMENTAL MYOSIN HEAVY CHAIN-POSITIVE FIBERS. ONLY THE REGENERATING AREA SHOWED INCREASED CAPILLARY DENSITY. THIS STUDY PROVIDES NOVEL EVIDENCE OF A VEGF BENEFICIAL EFFECT IN MDX MICE THAT IS EXERTED MAINLY BY A PROREGENERATIVE AND ANGIOGENIC EFFECT. IT OPENS NEW THERAPEUTIC PROSPECTIVES IN DMD AND OTHER TYPES OF MUSCULAR DISORDERS. THE FASEB JOURNAL 2007;21:3737-3746. ANNO: 2007 - ISBN: EVIDENCE OF CARDIOVASCULAR AUTONOMIC IMPAIRMENT IN MITOCHONDRIAL DISORDERS DI LEO R, MUSUMECI O, DE GREGORIO C, RECUPERO A, GRIMALDI P, MESSINA C, COGLITORE S, VITA G, TOSCANO A.

of 13 OBJECTIVE: TO INVESTIGATE AUTONOMIC NERVOUS SYSTEM (ANS) FUNCTION IN MITOCHONDRIAL DISORDERS (MD). BACKGROUND: MD ARE CHARACTERIZED BY A WIDE RANGE OF CLINICAL FEATURES, INCLUDING HEART ABNORMALITIES AND PERIPHERAL AND CENTRAL NERVOUS SYSTEMS INVOLVEMENT. RARELY AUTONOMIC SYMPTOMS HAVE BEEN REPORTED. METHODS: 22 PATIENTS WITH MD UNDERWENT A BATTERY OF CARDIOVASCULAR REFLEX TESTS INCLUDING FIVE TESTS OF PARASYMPATHETIC FUNCTION AND FOUR TESTS OF SYMPATHETIC FUNCTION. POWER SPECTRAL ANALYSES (PSA) OF HEART RATE VARIABILITY IN THE SUPINE AND UPRIGHT POSITIONS WERE ALSO EVALUATED. PLASMA LEVELS OF ADRENALINE, NORADRENALINE AND DOPAMINE WERE DETERMINED IN THE STANDING AND LYING POSITIONS. RESULTS: ONLY 4/22 PATIENTS REFERRED SYMPTOMS RELATED TO ANS DYSFUNCTION. 46% OF PATIENTS HAD A DEFINITE AUTONOMIC DAMAGE (I. E. AN AUTONOMIC SCORE 4). 36% SHOWED MODERATE ALTERATIONS WITH AN AUTONOMIC SCORE IN THE RANGE 2 3 AND 18 % HAD A NORMAL AUTONOMIC FUNCTION. MD PATIENTS HAD A SIGNIFICANTLY (P<0.03) LOWER INCREASE OF ADRENALINE LEVEL AFTER STANDING. CONCLUSIONS: OUR DATA INDICATE AN AUTONOMIC DYSFUNCTION IN MORE THAN 80% OF MD PATIENTS, EVEN IN THE ABSENCE OF A CLINICALLY MANIFESTED AUTONOMIC INVOLVEMENT. CARDIOVASCULAR AUTONOMIC INVESTIGATION MIGHT BE SYSTEMATICALLY EMPLOYED IN THE CHARACTERIZATION OF MD. JOURNAL OF NEUROLOGY 2007;254:1498-1503. ANNO: 2007 - ISBN: TRATTATO DI NEUROPATOLOGIA MANCARDI GL, TAGLIAVINI F, VITA G. CONTATTO & ARCHIMEDICA, TORINO 2006 ANNO: 2006 - ISBN: CAPACITÀ E COMPETENZE PERSONALI ATTIVITA' SCIENTIFICA AUTORE DI NUMEROSE PUBBLICAZIONI SU RIVISTE CON IMPACT FACTOR, CON PARTICOLARE RIGUARDO ALLE SEGUENTI TEMATICHE: MALATTIE NEUROMUSCOLARI, DISTROFIE MUSCOLARI, MIOPATIE CONGENITE, MIOPATIE METABOLICHE, MIOPATIE MITOCONDRIALI, PROTEINE CITOSCHELETRICHE DELLA FIBRA MUSCOLARE E DEL NERVO PERIFERICO, ATROFIE MUSCOLARI SPINALI, NEUROPATIE GENETICHE ED ACQUISITE, NEUROPATIE AUTONOMICHE.

of 13 PRIMA LINGUA ITALIANO ALTRE LINGUE INGLESE Capacità di lettura ECCELLENTE Capacità di scrittura ECCELLENTE Capacità di espressione orale ECCELLENTE FRANCESE Capacità di lettura BUONO Capacità di scrittura BUONO Capacità di espressione orale BUONO CAPACITÀ E COMPETENZE RELAZIONALI INCARICHI SCIENTIFICI 2000-2003 FONDATORE E 1 PRESIDENTE DELL ASSOCIAZIO NE ITALIANA DI MIOLOGIA 2001-2002 PRESIDENTE DELL ASSOCIAZIONE ITALIANA DI NEUROPATOLOGIA 2007-2010 MEMBRO DEL EXECUTIVE BOARD DELLA WORLD MUSCLE SOCIETY 2008-2010 PRESIDENTE DELLA ASSOCIAZIONE ITALIANA PER LO STUDIO DEL SISTEMA NEUROVEGETATIVO

of 13 CAPACITÀ E COMPETENZE ORGANIZZATIVE DIRETTORE DEL DIPARTIMENTO DI NEUROSCIENZE, SCIENZE PSICHIATRICHE ED ANESTESIOLOGICHE DELL'UNIVERSITÀ DI MESSINA. DELEGATO DEL RETTORE PER LA DIDATTICA DELL'AREA SCIENTIFICA TECNOLOGICA. COORDINATORE DEL DOTTORATO DI RICERCA IN "RICERCA CLINICA E TRASLAZIONALE IN NEUROSCIENZE E ONCOLOGIA". HA ORGANIZZATO XXVII CONGRESSO DELL'ASSOCIAZIONE ITALIANA DI NEUROPATOLOGIA, TAORMINA 1991. XXXV CONGRESSO DELL'ASSOCIAZIONE ITALIANA DI NEUROPATOLOGIA, LIPARI 1999. IV CONGRESSO DELL'ASSOCIAZIONE ITALIANA DI MIOLOGIA E IX RIUNIONE DEL GRUPPO DI STUDIO DEL SISTEMA NERVOSO VEGETATIVO -CONGRESO CONGIUNTO, TAORMINA 2004. XII INTERNATIONAL CONGRESS OF THE WORLD MUSCLE SOCIETY, GIARDINI NAXOS 2007. XII CONGRESS OF THE EUROPEAN FEDERATION OF AUTONOMIC SOCIETIES, GIARDINI NAXOS 2010. XII INTERNATIONAL CONGRESS ON NEUROMUSCULAR DISEASES, NAPOLI 2010. PROGETTI DI RICERCA FINANZIATI RESPONSABILE DI UNITÀ DI RICERCA IN PROGRAMMI FINANZIATI DALLA FONDAZIONE TELETHON (2002, 2003, 2004, 2005, 2007, 2008), AIFA (2006, 2008) E DAL MINISTERO DELLA SALUTE, RICERCA SANITARIA FINALIZZATA (2002); COORDINATORE SCIENTIFICO DI PROGRAMMA DI RICERCA COFIN-MIUR 2004; PARTNER DI SPECIFIC SUPPORT ACTION FINANZIATA DALLA COMMISSIONE EUROPEA, 6 PROGRAMMA QUADRO (2005). RESPONSABILE DEL PROGETTO DIDATTICO INTERNAZIONALE TEMPUS MEDA EDUCATION CURRICULA PROJECT IN REHABILITATION, FINANZIATO DALLA COMMISSIONE EUROPEA (2006-2009). CAPACITÀ E COMPETENZE TECNICHE DAL 2000 CORRESPONDING MEMBER OF THE AMERICAN NEUROLOGICAL ASSOCIATION DAL 2002 ESPERTO DEL MINISTERO DELLA SALUTE PER IL PROGRAMMA DI ECM ESPERIENZE DI TRIAL CLINICI TACS STUDY: TICLOPIDINE AND ASPIRINE COMBINATION FOR STROKE (PHASE III) DESTRO STUDY: MINOR DEPRESSION IN POST-STROKE (PHASE III) SITS-MOST STUDY: SAFE IMPLEMENTATION OF THROMBOLYSIS IN STROKE MONITORING STUDY (PHASE III) SMART STUDY: SPINAL MUSCULAR ATROPHY RANDOMISED CLINICAL TRIAL WITH GABAPENTIN (PHASE II) QUALITY OF LIFE AND DISABILITY IN PATIENTS WITH CHARCOT-MARIE- TOOTH DISEASE: A MULTICENTRE AND MULTIPERSPECTIVE FOLLOW- UP DOUBLE BLIND CLINICAL STUDY WITH TRIBUTYRATE IN PATIENTS WITH SPINAL MUSCULAR ATROPHY (PHASE II) CMT TRIAAL: MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO- CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN

of 13 CHARCOT-MARIE-TOOTH DISEASE TYPE 1A PHASE II, RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY OF TOLERANCE AND EFFICACY OF SALBUTAMOL IN ADULT PATIENTS WITH SPINAL MUSCULAR ATROPHY TYPE III ALLEGATI 1) ELENCO DELLE PRINCIPALI PUBBLICAZIONI DEGLI ULTIMI 5 ANNI